8-K: ADC Therapeutics Reports Q2 2025 Results, Extends Runway

ADC Therapeutics announced its second quarter 2025 financial results, highlighted by strong ZYNLONTA clinical data, a $100 million PIPE financing extending cash runway into 2028, and a strategic restructuring.

Summary

• Net product revenues were $18.1 million for the second quarter ended June 30, 2025, and $35.5 million for the first six months of 2025.
• Net loss for the second quarter ended June 30, 2025, was $56.6 million, or $0.50 per basic and diluted share.
• Net loss for the six months ended June 30, 2025, was $95.2 million, or $0.86 per basic and diluted share.
• Completed a $100 million private investment in public equity (PIPE) financing, resulting in net proceeds of $93.1 million, extending the expected cash runway into 2028.
• Cash and cash equivalents were $264.6 million as of June 30, 2025, compared to $250.9 million as of December 31, 2024.
• The LOTIS-7 Phase 1b clinical trial of ZYNLONTA in combination with glofitamab demonstrated an overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in 30 efficacy evaluable patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
• The LOTIS-5 Phase 3 trial is on track to reach prespecified progression-free survival (PFS) events by the end of 2025.
• A strategic restructuring and prioritization plan was announced, discontinuing early development efforts for preclinical solid tumor programs and focusing on ZYNLONTA.
• The restructuring includes the planned shutdown of the UK facility and a reduction of the global workforce by approximately 30%, expected to be substantially completed by September 30, 2025.
• Incurred $13.1 million in restructuring and impairment costs for the three and six months ended June 30, 2025, consisting of $6.7 million in employee severance and $6.4 million in non-cash asset impairment.

Sentiment

Score: 6

Explanation: The filing presents a mixed bag of strong clinical data and a significant capital raise extending the cash runway, which are positive. However, these are offset by a substantial increase in net loss, driven by higher R&D and significant restructuring costs including a 30% workforce reduction and facility closure, indicating underlying financial pressures and a need for strategic refocusing.

Positives

• Strong efficacy data from the LOTIS-7 study, showing a 93.3% overall response rate and an 86.7% complete response rate for ZYNLONTA plus glofitamab in r/r DLBCL patients.
• Successful completion of a $100 million PIPE financing, providing $93.1 million in net proceeds and extending the expected cash runway into 2028.
• LOTIS-5 Phase 3 trial remains on track to reach prespecified progression-free survival events by the end of 2025, indicating progress towards potential confirmatory approval.
• Increased net product revenues for Q2 2025 ($18.1 million vs $17.0 million in Q2 2024) and H1 2025 ($35.5 million vs $34.9 million in H1 2024).
• Decreases in Selling and Marketing expense ($10.1 million in Q2 2025 vs $10.7 million in Q2 2024) and General & Administrative expense ($8.8 million in Q2 2025 vs $10.2 million in Q2 2024) due to cost reduction efforts.
• Positive updated data from an investigator-initiated trial demonstrating ZYNLONTA's potential as a monotherapy in r/r marginal zone lymphoma, with an 84.6% ORR and 69.2% CR.

Negatives

• Increased net loss for Q2 2025 ($56.6 million compared to $36.5 million in Q2 2024) and H1 2025 ($95.2 million compared to $83.2 million in H1 2024).
• Higher Research and Development expense ($30.1 million in Q2 2025 vs $24.3 million in Q2 2024) driven by clinical trial timing and enrollment, and IND-enabling activities.
• Incurred $13.1 million in restructuring and impairment costs in Q2 2025 due to the strategic reprioritization.
• The strategic restructuring involves a reduction of the global workforce by approximately 30% and the shutdown of the UK facility.

Risks

• The success of the strategic restructuring plan and changes in associated costs, including workforce reduction and UK facility closure.
• The expected cash runway into 2028 assumes the use of minimum liquidity required under loan agreement covenants.
• Future LOTIS-7 clinical trial results may not be consistent with or different from the data presented at EHA and ICML.
• The timing of PFS events for LOTIS-5 and the results of the trial, as well as the timing of full FDA approval for ZYNLONTA.
• Future safety and efficacy results of the Phase 2 investigator-initiated trial in marginal zone lymphoma and any potential regulatory or compendia pathways.
• The company's ability to grow ZYNLONTA revenue in the United States and achieve potential peak revenue.
• The ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments from such partnerships, and their ability to obtain regulatory approval.
• The timing and results of the company's or its partners' research and development projects or clinical trials, including LOTIS-5, LOTIS-7, and early pre-clinical research for the exatecan-based ADC targeting PSMA.
• The timing and results of investigator-initiated trials, including those studying follicular lymphoma and marginal zone lymphoma, and the potential regulatory and/or compendia strategy.
• The timing and outcome of regulatory submissions for the company's products or product candidates.
• Actions by the FDA or foreign regulatory authorities.
• Projected revenue and expenses may differ from actual outcomes.
• The company's indebtedness, including facilities with Healthcare Royalty Management, Blue Owl, and Oaktree, and the restrictions imposed by such indebtedness, the ability to comply with agreement terms, repay indebtedness, and the significant cash required to service it.
• The company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities.
• Uncertainties of international trade policies, including tariffs, sanctions, and trade barriers, and their potential impact on the business, financial condition, and results of operations.

Future Outlook

The company expects to engage with the U.S. FDA and provide an update on the LOTIS-7 trial in the second half of 2025. LOTIS-5 is on track to reach prespecified PFS events by the end of 2025, with topline data expected once available. A potential supplemental Biologics License Application (sBLA) submission for ZYNLONTA in 2L+ DLBCL is anticipated in the first half of 2026, with potential confirmatory approval and publication/compendia inclusion in the first half of 2027. IND-enabling activities for the PSMA-targeting ADC are expected to be completed by the end of 2025. Publication and compendia inclusion for ZYNLONTA monotherapy in r/r MZL is anticipated in the first half of 2027.

Management Comments

• "Entering the second half of 2025, we have streamlined our strategic focus and strengthened our financial foundation, which now allows us to pursue multiple promising opportunities to expand ZYNLONTA into earlier lines of therapy in DLBCL and indolent lymphomas." Ameet Mallik, Chief Executive Officer.
• "We recently shared impressive efficacy data from our LOTIS-7 study of ZYNLONTA plus glofitamab in patients with relapsed or refractory DLBCL and have additional key clinical milestones anticipated through 2026." Ameet Mallik, Chief Executive Officer.
• "These milestones include LOTIS-5 achieving the prespecified PFS event target this year and a ZYNLONTA sBLA filing anticipated in 2026, in addition to ongoing Phase 2 investigator-initiated trials in indolent lymphomas." Ameet Mallik, Chief Executive Officer.
• "We remain committed to executing our strategy with discipline as we pursue the substantially larger therapeutic opportunity for ZYNLONTA." Ameet Mallik, Chief Executive Officer.

Industry Context

ADC Therapeutics operates in the highly competitive and rapidly evolving oncology biopharmaceutical sector, specifically focusing on Antibody Drug Conjugates (ADCs). The strong clinical data for ZYNLONTA, particularly in combination with glofitamab (COLUMVI), positions it favorably against other treatments for relapsed/refractory DLBCL. The strategic restructuring to focus solely on ZYNLONTA and the PSMA-targeting ADC reflects a common industry trend of prioritizing core assets and streamlining operations to extend financial runways, especially for companies with commercial-stage products facing significant R&D costs. The successful PIPE financing demonstrates continued investor confidence in the ADC platform and ZYNLONTA's market potential.

Comparison to Industry Standards

• ZYNLONTA's 93.3% Overall Response Rate (ORR) and 86.7% Complete Response (CR) in LOTIS-7 (ZYNLONTA + glofitamab) for r/r DLBCL are highly competitive. For comparison, glofitamab (COLUMVI) monotherapy itself has shown a CR rate of 39.2% in a similar patient population (NP30179 study). The combination data suggests a synergistic effect, potentially outperforming monotherapy or other established regimens like CAR T-cell therapies (which have CR rates ranging from 40-60% in r/r DLBCL, but with different safety profiles and logistical challenges).
• The 84.6% ORR and 69.2% CR for ZYNLONTA monotherapy in r/r marginal zone lymphoma (MZL) are also strong, indicating potential for expansion beyond DLBCL. Other approved treatments for MZL, such as rituximab, often show lower CR rates in relapsed settings.
• The $100 million PIPE financing and extended cash runway into 2028 are crucial in the biotech industry, where capital raises are frequent and cash burn is high. This provides a more stable financial footing compared to many smaller biotechs that face shorter runways and more frequent dilution.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased value from ZYNLONTA's expanded indications and extended cash runway, but also dilution from the PIPE financing and impact of increased net losses and restructuring costs.
• Employees: Significant impact due to approximately 30% global workforce reduction and closure of the UK facility.
• Customers (Patients/Healthcare Providers): Potential for new treatment options with ZYNLONTA's expanded indications (DLBCL, MZL) and future pipeline (PSMA-targeting ADC).
• Creditors: The extended cash runway into 2028 provides greater financial stability, potentially reducing immediate concerns about debt servicing.
• Suppliers: Potential impact from reduced operations due to restructuring and closure of the UK facility.

Next Steps

• Expand LOTIS-7 Phase 1b trial to 100 r/r DLBCL patients.
• Share additional LOTIS-7 data in the second half of 2025.
• Engage with the U.S. FDA and provide an update on the LOTIS-7 trial in the second half of 2025.
• Pursue publication and compendia inclusion for LOTIS-7 data in the first half of 2027.
• Provide topline data for LOTIS-5 Phase 3 trial once PFS events are reached and data are available (expected by end of 2025).
• Anticipate supplemental Biologics License Application (sBLA) submission to regulatory authorities in the first half of 2026 for ZYNLONTA in 2L+ DLBCL.
• Anticipate potential confirmatory approval for ZYNLONTA in 2L+ DLBCL and publication/compendia inclusion in the first half of 2027.
• Assess a potential regulatory pathway for ZYNLONTA as monotherapy in r/r marginal zone lymphoma.
• Anticipate potential publication and compendia inclusion for ZYNLONTA monotherapy in r/r MZL in the first half of 2027.
• Complete IND-enabling activities for the PSMA-targeting ADC by the end of 2025.
• Substantially complete global workforce reduction by September 30, 2025.
• Shut down UK facility.

Key Dates

Recommendation

While the clinical data for ZYNLONTA is very promising and the PIPE financing significantly extends the cash runway, the company is undergoing a substantial restructuring, including a 30% workforce reduction and increased net losses. This indicates a period of significant transition and cost management. Investors should hold to observe the execution of the strategic refocus, the impact of the restructuring on future operations, and the progression of the LOTIS-5 and LOTIS-7 trials towards regulatory approvals before making further investment decisions. The positive clinical data and extended runway provide a floor, but the operational challenges and increased losses warrant caution.

Keywords

ADC Therapeutics, ADCT, ZYNLONTA, loncastuximab tesirine-lpyl, antibody drug conjugates, DLBCL, diffuse large B-cell lymphoma, relapsed refractory, r/r DLBCL, LOTIS-7, LOTIS-5, glofitamab, COLUMVI, marginal zone lymphoma, MZL, PSMA-targeting ADC, exatecan, PIPE financing, Q2 2025 earnings, financial results, clinical trials, oncology, hematology, biopharmaceutical, restructuring